LONA
LeonaBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.56
−1.82%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +4.6%
- EBIT
- -98.4%
- EPS
- —
- Free cash flow
- +12.4%
- Operating cash flow
- +12.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +91.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- +65.3%
- EBIT
- -1.4%
- Net income
- -8.9%
- EPS
- +2.0%
- Free cash flow
- +53.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026